1. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Issue 2 (16th November 2016) Authors: Ungar, B.; Kopylov, U.; Engel, T.; Yavzori, M.; Fudim, E.; Picard, O.; Lang, A.; Williet, N.; Paul, S.; Chowers, Y.; Bar‐Gil Shitrit, A.; Eliakim, R.; Ben‐Horin, S.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 2(2017) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial. Issue 2 (27th April 2017) Authors: Roblin, X.; Boschetti, G.; Williet, N.; Nancey, S.; Marotte, H.; Berger, A.; Phelip, J. M.; Peyrin‐Biroulet, L.; Colombel, J. F.; Del Tedesco, E.; Paul, S.; Flourie, B. Journal: Alimentary pharmacology & therapeutics Issue: Volume 46:Issue 2(2017) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease. (20th April 2015) Authors: Roblin, X.; Marotte, H.; Leclerc, M.; Del Tedesco, E.; Phelip, J.M.; Peyrin-Biroulet, L.; Paul, S. Journal: Journal of Crohn's and colitis Issue: Volume 9:Number 7(2015:Jul.) Page Start: 525 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. Issue 7 (31st January 2018) Authors: Yacoub, W.; Williet, N.; Pouillon, L.; Di‐Bernado, T.; De Carvalho Bittencourt, M.; Nancey, S.; Lopez, A.; Paul, S.; Zallot, C.; Roblin, X.; Peyrin‐Biroulet, L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 7(2018) Page Start: 906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease. Issue 4 (30th June 2014) Authors: Seirafi, M.; de Vroey, B.; Amiot, A.; Seksik, P.; Roblin, X.; Allez, M.; Peyrin‐Biroulet, L.; Marteau, P.; Cadiot, G.; Laharie, D.; Boureille, A.; De Vos, M.; Savoye, G.; Rahier, J.‐F.; Carbonnel, F.; Bonaz, B.; Colombel, J.‐F.; Bouhnik, Y. Journal: Alimentary pharmacology & therapeutics Issue: Volume 40:Issue 4(2014) Page Start: 363 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Issue 10 (21st March 2013) Authors: Laharie, D.; Filippi, J.; Roblin, X.; Nancey, S.; Chevaux, J.‐B.; Hébuterne, X.; Flourié, B.; Capdepont, M.; Peyrin‐Biroulet, L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 37:Issue 10(2013) Page Start: 998 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort. Issue 4 (18th December 2017) Authors: Tadbiri, S.; Peyrin‐Biroulet, L.; Serrero, M.; Filippi, J.; Pariente, B.; Roblin, X.; Buisson, A.; Stefanescu, C.; Trang‐Poisson, C.; Altwegg, R.; Marteau, P.; Vaysse, T.; Bourrier, A.; Nancey, S.; Laharie, D.; Allez, M.; Savoye, G.; Gilletta, C.; Gagniere, C.; Vuitton, L. Other Names: Amiot Aurelien investigator.; Gagniere Charlotte investigator.; Serrero Melanie investigator.; Grimaud Jean‐Charles investigator.; Peyrin‐Biroulet Laurent investigator.; Zallot Camille investigator.; Bigard Marc‐Andre investigator.; Filippi Jerome investigator.; Hebuterne Xavier investigator.; Pa... Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 4(2018) Page Start: 485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (2nd February 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (March 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Letter: extracorporeal photopheresis in refractory chronic active ulcerative colitis. Issue 4 (16th July 2013) Authors: Nancey, S.; Boschetti, G.; Moussata, D.; Hequet, O.; Roblin, X.; Flourié, B. Journal: Alimentary pharmacology & therapeutics Issue: Volume 38:Issue 4(2013) Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗